Investors
Cell Tech is a clinical stage biotech company advancing their FDA and Health Canada-approved stem cell technology to market.
Stem Cell Innovation
Regenerative medicine market is expected to grow to USD $150B by 2028 with 23.5% CAGR and be an active investment area for pharmaceutical companies, including Astellas, J&J and Fujifilm.
Market Outlook
Osteoarthritis (OA) and Degenerative Disk Disease are two common chronic diseases affecting millions of people globally with devastating medical and economic impacts.
Chronic Pain Solutions
Cell Tech’s unique position is based on our proprietary technology with a solid moat of 6 patents and multiple publications. Our stem cells can specifically target and treat arthritis. Human studies validating the technology demonstrating impressive success.
Unique Position
Cell Tech is launching a late-stage trial and eyeing Exclusive Market Authorization (EMA) in Canada advancing stem cell therapy for Osteoarthritis.